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A study of health-related quality of life in pediatric atopic dermatitis 
 
INTRODUCTION 
Atopic dermatitis is a complex, chronic 
inflammatory skin disorder with significant 
morbidity. It is often a frustrating condition for both 
children and parents due to chronic and relapsing 
course.1 It is a complex immune mediated disease 
characterized by intense pruritus commonly 
beginning in childhood/infancy persisting or 
recurring in adulthood or presenting as adult onset 
disease.2,3 The substantial public health impact of 
AD on population general health was established by 
the 2010 Global Burden of Skin Disease project and 
validated by the Cochrane Skin Group in 2014. In 
this context, skin diseases are considered the fourth 
leading cause of nonfatal disease burden among all 
chronic diseases. AD was particularly implicated as 
responsible for the greatest population-level 
disability.4 
Skin conditions have a negative impact on 
emotional status, social relationships and daily 
activities. Chronic pruritus is often untreatable, so it 
has a major impact on the QOL, as it affects the 
quality of sleep and children’s behaviour as well as 
their productivity. Parents of the affected children 
reported difficulties in discipline and in caring for 
their children.5-7 AD is associated with physical 
comorbidities, such as allergic rhinitis and asthma, 
which leads to more psychiatric comorbidities 
including depression up to suicidal thoughts. 
Patients with AD were noted 50 years ago to have a 
characteristic psychological profile, especially in 
anxiety and depression, that differs from patients 
with other cutaneous diseases.8,9 
A number of potential theories might explain the 
exact relation between AD and psychiatric illness. 
First, it is possible that changes in inflammatory 
markers contribute to psychiatric derangement. 
Second, there is a well-known link between sleep 
disturbance and depression in the general 
population. A number of studies noted an increase 
in sleep disturbances in patients with AD compared 
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to non-atopic patients, which may contribute to an 
increased risk of depression. Third, pruritus which 
is a major symptom of AD is linked to depression 
and even suicidal ideation and the severity of itch is 
positively correlated with the severity of 
depression.10-13 
QOL has gained extreme importance as an 
integrated part of the management of the chronic 
diseases. Children with chronic health conditions 
become physically, socially, and spiritually. 
Moreover, the negative impact of the chronic illness 
on the QOL extends from the children to their 
families.14-16 Improving HRQOL is a major goal in 
the management of chronic diseases. The study of 
QOL is an examination of influences upon 
goodness and meaning in life as well as people’s 
happiness and wellbeing.16,17  
We sought to estimate, through validated 
questionnaires, the impact of AD on the quality of 
life of those children and their parents and/or 
caregivers. The ultimate objective is to outline the 
exact deleterious effects of AD on HRQOL and 
hence be able to design measures that would 




This analytical cross-sectional study was conducted 
on 85 children with physician diagnosed AD and 
their caregivers. They were recruited from the 
Pediatric Allergy and Immunology Unit, Children's 
Hospital, Ain Shams University during the period 
from May 2018 to December 2019. The study 
gained approval by the local ethics’ committee of 
the Department of Pediatrics, Ain Shams 
University. Informed consent was obtained from the 
parents or caregivers prior to enrollment.  
We excluded children with concomitant chronic 
illness and/or significant social, medical or 
environmental problems unrelated to AD. 
 
All children enrolled in the study were subjected 
to the following: 
▪ Clinical evaluation including age, sex, 
socioeconomic status, family history of AD or 
atopy, presence of other allergies, frequency of 
outpatient clinic visits and frequency of 
exacerbations. Other data included age at onset, 
age at diagnosis, diagnostic lag, surface area 
affected and treatment received. Clinical 
examination was performed to assess the presence 
of any complications, active disease or other 
associated allergies. 
▪ Patient and parent data were collected using 
individual questionnaires conducted by the 
investigator directed to the children and their 
caregivers.  
▪ HRQOL was assessed using The Children’s 
Dermatology Life Quality Index (CDLQI) which 
consists of 10 items and covers symptoms and 
feelings, leisure, personal relationships, sleep, 
school and holiday info and treatment. 
▪ Children were divided into two groups: group 1: 
aged 5 years and above who were able to answer 
the whole questions of the CDLQI 
questionnaire;18 and group 2: aged below 5 years. 
Parents/caregivers of group 2 were inquired for 
just 3 questions from the whole questionnaire 
which are questions about severity of itching; 
effect of the disease on the choice of their clothes 
and effect of the disease on their sleep, as the rest 
of the questions are not applicable for age. 
▪ HRQOL for the parents/caregivers was assessed 
using The Family Dermatology Life Quality Index 
(FDLQI) which consists of 10 items and covers 
social, emotional and physical aspects as well as 
financial burden.19 
Interpretation 
For both CDLQI and FDLQI, each question was 
scored as follows:  
− Very much = 3 
− Quite a lot = 2  
− Only a little = 1  
− Not at all = 0 
Total score ranges from a maximum of 30 and a 
minimum of 0: 
− 0 and 1: no effect 
− 2 to 6: small effect 
− 7 to 12: moderate effect  
− 13 to 18: very large effect  
− 19 to 30: extremely large effect 
 
Statistical Analysis 
The collected data was revised, coded and tabulated 
and introduced to a PC using Statistical Package for 
Social Science (SPSS 13.0.1 for windows; SPSS 
Inc, Chicago, IL, 2001). 
• Descriptive statistics: Mean and standard 
deviation (SD) for numerical data; frequency and 
percentages for non-numerical data. 
• Analytical statistics: Student T test was used to 
assess the statistical significance of the difference 
between two study group means. Chi-square test 
was used to examine the relationship between two 
qualitative variables. Correlation analysis (using 
Pearson’s method): to assess the strength of 
association between two quantitative variables. 
The correlation coefficient denoted symbolically 
“r” defines the strength (magnitude) and direction 
(positive or negative) of the linear relationship 
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between two variables: r = 0-0.19 is regarded as 
very weak correlation, r = 0.2-0.3 is regarded as 
weak correlation, r = 0.40-0.59 is regarded as 
moderate correlation, r = 0.6-0.79 is regarded as 




This study was conducted on 85 children, aged 
between 1-14 years, 65 of them were above 5 years 
of age and 20 of them were below 5. Boys formed 
76.5% and girls 23.5% of the studied sample. Most 
of the children had eczema in the face (89.4%), 
followed by the flexural sites (78.8%) and to less 
extent in the extensor surfaces (44.7%). Less than 
half of the patients had positive family history of 
atopy and 60% of them had personal history of 
other allergies including bronchial asthma, allergic 
rhinitis and food allergies (Table 1). All the 
children were on treatment, varying among topical 
emollients, topical corticosteroids and oral second-
generation antihistamines. None of them were on 
systemic corticosteroids or immunosuppressant. 
Self-reported adverse effects of medications were 
more frequent in the older age group. (Table 2)   
Upon analyzing the QOL of the children with 
AD according to CDLQI questionnaire we found 
that more than half of studied children had an 
extremely affected QOL (55.4%). The most 
common affected domains were the symptoms and 
feelings and leisure followed by sleep and personal 
relationship domains, while the least affected 
domain was school and holiday aspects (Figure1) . 
The main factors that had significant effect on 
children’s QOL were the face eczema, presence of 
other allergies and presence of self-reported adverse 
effects of treatment (Table 3). Most of our patients 
did not report adverse effects from the used 
medications; only 17 had itching and 17 suffered 
from skin infection and none of them had 
lichenification or disfigurement. However, the 
presence of adverse effects was associated with 
extreme alteration of the HRQOL. None of the 
studied children was using oral corticosteroids or 
immunosuppressants for treatment . 
Upon analyzing the HRQOL scores of the 
families of the children with AD according to 
FDLQI questionnaire, we found that about two 
thirds of them had very large to extremely impaired 
QOL (65.9%), and 20% of them had moderate to 
small affection of their QOL. The QOL was not 
affected in only 14.4% of them. The most affected 
was the emotional domain (83.5%) followed by 
treatment burden (82.4%), physical domain 
(81.2%), time needed for care (80%), and social 
domain (78.8%) and the least affected were the 
personal relationships (62.4%); Figure 2 . 
The main factors that had significant effect on 
families’ QOL were: having other diseased sib, 
suffering of the affected child from other allergies 
and presence of self-reported adverse effects of 
medications used (table 4) . 
Noticeably, the HRQOL of the 
parents/caregivers was positively correlated to the 
QOL of their affected children meaning that the 
poor HRQOL of children may also impair their 




Table 1. Site of AD lesions, history of allergy and rate of health care visits in the studied sample 
 
Site of lesions 
Face 76 (89.4%) 
Flexures 67 (78.8%) 
Extensors 38 (44.7%) 
Family history 
Negative 51 (60.0%) 
Positive 34 (40.0%) 
Other sib affection 
Negative 62 (72.9%) 
Positive 22 (27.1%) 
Other allergies 
Negative 34 (40.0%) 
Positive 51 (60.0%) 
Outpatient clinic visits (per 6 month) 
Mean ± SD 
Range 
2.21 ± 2.03 
0-8 
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Table 2. Types and self-reported adverse effects of medications used in studied sample 
 
Treatment modality Use Number % 
Emollients No 12 14.1% 
Yes 73 85.9% 
Non-sedating antihistamines No 19 22.4% 
Yes 66 77.6% 
Topical corticosteroids No 46 54.1% 
Yes 39 45.9% 
Adverse effects of topical treatment Score 0 47 55.3% 
Score 1 19 22.4% 
Score 2 19 22.4% 
Score 3 0 0% 







Table 3. Correlations between the demographic and clinical data of the AD children above 5 years of age 





Small to  
moderate (no 7) 
Very large to  
extreme (no 53) 
Test P 
Age (yr.) 
Mean (SD) 7.80 (1.79) 7.36 (2.87) 8.93 (2.71) 
3.062 0.216 
Range 6 – 10 5 – 13 5 – 14 
Sex 
Male 4 (80.0%) 4 (57.1%) 42 ± 79.2% 
1.731 0.421 
Female 1 (20.0%) 3 (42.9%) 11 – 20.8% 
Age of Onset  
(month) 
Mean (SD) 22.20 (10.31) 39.00 (51.47) 22.53 (17.69) 
0.418 0.811 
Range 12 – 36 3 – 150 1 –84 
Diagnostic lag  
(month) 
Mean (SD) 3.60 ± 1.82 7.29 (7.83) 12.49 (25.29) 
0.551 0.759 
Range 2 – 6 2 – 24 1 –120 
Site affection 
Face 2 (40.0%) 6 (85.7%) 48 (90.6%) 9.795 0.007* 
Flexures 5 (100.0%) 6 (85.7%) 47 (88.7%) 0.710 0.701 
Extensor surfaces 2 (40.0%) 2 (28.6%) 26 (49.1%) 1.127 0.569 
Family history 
Negative 2 (40.0%) 4 (57.1%) 28 (52.8%) 
0.375 0.829 
Positive 3 (60.0%) 3 (42.9%) 25 (47.2%) 
Other sib affection 
Negative 5 (100.0%) 5 (71.4%) 34 (64.2%) 
2.735 0.255 
Positive 0 (0.0%) 2 (28.6%) 19 (35.8%) 
Other allergies 
Negative 5 (100.0%) 6 (85.7%) 15(28.3%) 
16.617 <0.001* 
Positive 0 (0.0%) 1 (14.3%) 38 (71.7%) 
Treatment 
Antihistamine 4 (80.0%) 6 (85.7%) 39 (73.6%) 0.552 0.759 
Emollient 4 (80.0%) 7 (100.0%) 43 (81.1%) 1.602 0.449 
Topical steroids 2 (40.0%) 2 (28.6%) 24 (45.3%) 0.725 0.696 
Adverse effects of 
treatment 
Score 0 5 (100.0%) 6 (85.7%) 20 (37.7%) 
11.956 0.018* Score 1 0 (0.0%) 1 (14.3%) 16 (30.2%) 
Score 2 0 (0.0%) 0 (0.0%) 17 (32.1%) 
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Table 4. Correlations between the demographic and clinical data of the AD children and their families’ 
HRQOL affection grades 
 
Data 
No effect Small to medium Very large to extreme 
Test P 




5.04 ± 2.8 
2 – 10 
7.56 ± 3.57 
1 – 14 
7.69 ± 3.4 
















22.3 ± 9.7 
12 – 36 
28.29 ± 34.31 
3 – 150 
21.3 ± 17.4 






5.75 ± 6.21 
2 – 24 
11.65 ± 20.74 
1 – 84 
11.0 ± 22.7 
1 – 120 
0.228 0.892 






















7 (58.3%) 9 (52.9%) 35 (62.5%) 
0.513 0.774 
5 (41.7%) 8 (47.1%) 21 (37.5%) 
Other sib affection 
Negative 
Positive 
11 (91.7%) 15 (88.2%) 36 (64.3%) 
6.272 0.043* 











Clinic visits  
(per 6 month) 
Mean (SD) 
Range 
1.42 ± 1.38 
0 – 4 
2.59 ± 2.50 
0 – 8 
2.27 ± 1.98 
































































Figure 1. Frequency of HRQOL disturbance in the AD children 
 


































The highest negative effect on in our AD children 
above 5 years of age was related to itching and pain 
which had the greatest impact followed by sleep 
and personal relationship domains, while the least 
affected domain was that of school and holiday 
aspects. Most of the children in our series said that 
itching, pain and discomfort problems are badly 
affecting their lives. Similarly, itching, sleep 
disruption, mood shifts and feeling problems were 
reported in several studies to affect children’s 
QOL.20,21 Other problems related to AD, like 
compliance on treatment, dressing, relationship 
with friends and disordered playing and 
entertainment and weak self-confidence were also 
reported.14 
Among our series, 84.6% of the children 
believed that the disease had great impact on their 
relationship with friends, play and children 
recreations, while this was reported in only 2% by 
some other investigators. The difference may be 
attributed to social and cultural variations in 
different societies.22 As a matter of fact, symptoms 
such as itching and scratching can consequently 
aggravate AD lesions resulting in significant sleep 
deprivation leading to exhaustion, emotional swings 
and impaired functioning.19,22 
We observed a statistically significant effect of 
facial eczema in particular on the HRQOL. This 
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comes in agreement with data from other studies 
that displayed the bad impact of facial lesions on 
the QOL of children.23 The social interaction is 
expected to be worse in children with facial eczema 
due to poor acceptance of their peers or frequent 
comments on their looks.  
Because not all domains of the CDLQI can be 
applicable to infants and children younger than 5 
years, we could not thoroughly make comparative 
analysis according to age. However, three domains 
(symptoms and feelings, sleep and leisure) were 
studied in the young group and revealed statistically 
comparable data to those above 5 years. Some 
relevant studies concluded that the most negative 
effect on QOL was related to the mood and itching 
in the youngest age group (0–4 years old) compared 
to itching and leisure/hobbies in older children.22,24 
Another group of investigators previously noted 
that the HRQOL mean score was more affected in 
younger than older children.25 
Data from the CDLQI questionnaire of 167 AD 
children, 5–16 years old, from Ukraine, Czech 
Republic, Singapore, and Italy were analyzed in a 
multicentre international study. Only in Czech 
children the overall CDLQI score was positively 
correlated with their age.24 Other reports did not 
find any significant association between child’s age 
and the QOL status due to AD.22,26,27 Amore recent 
publication reported that the QOL measured by 
CDLQI was more impaired in younger children, 
whilst child mood was more impaired in older 
infants. The most impaired QOL was seen in 
children in the age group 5–9 years. The authors 
concluded that treatment and counseling of children 
suffering from AD should be tailored specifically to 
their age.28 Study design variations as well as 
cultural and social factors may explain the 
difference between various reports. 
In the current study, gender of patients had no 
effect on the HRQOL scores of patients and their 
families, which matches observations in some 
relevant studies.14,29 A gender effect might be 
expected in adolescents and those were not included 
in our series. 
Only 45.9% of our patients were adherent to 
their topical corticosteroid prescription. Although 
adverse effects of topical corticosteroids are 
minimal when used appropriately, caregiver fears 
related to topical corticosteroids were commonly 
mentioned among our series. Patients with AD 
should be assured that topical corticosteroids are the 
mainstay of treatment and that their prompt use in 
the flare-ups is the optimal approach.30 Such 
education may lessen their concerns. A recent meta-
analysis showed that health education improves 
SCORing Atopic Dermatitis (SCORAD) index of 
severity and quality of life as indicated by the 
Infants' Dermatology Quality of Life Index.31 
Indeed, promoting disease control through health 
education would improve the QOL. 
AD had a profound impact on personal, social, 
emotional and financial perspectives of the 
children’s families in the current study. It was 
assumed by some investigators that the impact of 
moderate and severe AD on QOL of families was 
even greater than that of insulin dependent diabetes 
mellitus.32 Our data also show a strong relationship 
between affection of sleep in children and familial 
physical disturbances. This was similarly concluded 
in a study that explored the relationship between 
childhood AD and its impact on parents’ health. A 
strong relationship was found between disruption of 
sleep of the child and parental anxiety and 
depression.33 As parents spend hours to comfort 
their children and manage their disease, they need 
to be prepared mentally and physically to be able to 
adapt to the consequences of sleep disturbance, 
emotional distress, and exhaustion.34 
More than half of affected parents/caregivers in 
our series suffered very large to extremely affected 
HRQOL (65.9%), while 20% had moderate to small 
affection and about 14.1% declared no effect on 
their QOL. The most frequently reported problems 
were the emotional distress (83.5%) and treatment 
burden (82.4%); this can be explained by limited 
treatment expense coverage by medical insurance 
that in turn, increases the financial burden on the 
families. Physical effort and time needed for care 
(81% and 80% respectively), social (78.8%) and 
personal relationship domains (62.4%) were 
affected as well. Such impact on family life was 
previously noted by another group of 
investigators.24,35 In our study, emotional distress in 
parents was found to be among the highest scoring 
items of FDLQI domains while tiredness and 
exhaustion were moderately reported; findings that 
conform with some other publications.36,37 Family 
leisure activities and relationship between family 
members were the least affected items of FDLQI in 
our study; this was not the case in a relevant 
study.37 It seems that leisure activities are not 
among the priorities of the Egyptian families 
especially that all our cases belong to the 
low/middle socioeconomic sector of the community 
who seek health care at our almost free-of-charge 
medical facility. 
We observed a significant impact of other sib 
affection, presence of other allergies in the affected 
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child and treatment adverse effects on the family’s 
QOL being more prevalent in parents with very 
large to extreme severity scores than those with no 
effect or less to moderate effect. It makes sense that 
families with more than one allergic member would 
experience greater QOL impairment due to 
compound treatment strategies and care-related 
tasks. 
Noteworthy is that the QOL of the children with 
AD was positively correlated to their caregivers 
QOL and that poor HRQOL of children impaired 
their caregivers’ mental and physical health aspects. 
This can be rationalized by the great burden on the 
parents and caregiver because of the special patient 
needs, such as bathing, wet dressing, topical 
application, and household-related tasks and 
responsibilities like food restrictions, cloth 
selection, laundry, and house cleaning to avoid 
potential allergens; all are exhausting and time-
consuming tasks. This combination of ongoing 
roles can have a profound effect on the QOL of 
caregivers. 
The point of strength in this pilot study is that it 
explores the HRQOL of the Egyptian children 
suffering from AD knowing that relevant published 
data from our country on chronic diseases are very 
scant. The study, nevertheless, has some 
limitations. First the sample size is limited and this 
hinders coming out with solid conclusions. Second, 
studied sub-groups are not equal and this is due to 
the consecutive enrolment of the subjects. This did 
not allow for accurate estimation of the influence of 
some variables such as the presence of other 
allergic disorders. A stratified non-random study 
design would be favorable in this aspect. Third, we 
did not include a healthy control group and this 
made us unable to analyze our results in respect to 
the quality of life of un-diseased Egyptian children 
and families living under similar socioeconomic 
circumstances. 
In conclusion, although AD is not categorized as 
a life-threatening condition, it is indeed a disease 
that affects multiple domains of QOL beginning as 
early as in infancy and sometimes persisting 
throughout life. The QOL of the children with AD 
was positively correlated to their caregivers QOL 
and this indicates that evaluation of the QOL in 
atopic dermatitis should not be limited to 
measurement of its impact on the patient because 
the QOL of all family members is adversely 
impacted as well. This necessitates paying more 
attention to the psychological, social and spiritual 
aspects in the children with AD and caring about 
parents’ psychosocial and financial burdens as 
intimate parts of the management of AD. We 
recommend Wider-scale controlled studies on the 
QOL assessment of AD patients as well as health 
education programs to help patients and their 
families adapt to the physical and psychological 
challenges they face. 
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